Moderna (MRNA) climbed to $81.42, up 169% annually. Analysts set average target at $37 while insiders sold $6.1M worth of ...
When a stock and the analysts covering it disagree this sharply, one of them is about to be wrong.
CNBC's Jim Cramer talks about his take on Moderna's stock performance and business outlook.
Moderna expands beyond vaccines while Recursion bets on AI-driven drug discovery, each with distinct risks, partnerships, and ...
Moderna just received fantastic news.
In a Q&A, Kenneth Chien, no longer with Moderna, predicts the company's mRNA cancer vaccine will be transformative for ...
Provides broad overview of Company's research and early development programs expected to continue to fuel future ...
The company's pending vaccine approvals could help the stock continue its rise.
Moderna (MRNA) stock jumps on Science Day pipeline update and FDA flu vaccine vote; see key catalysts, technical levels, and ...
Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...
Shares of Moderna (NASDAQ:MRNA | MRNA Price Prediction) are up 14% to $68 and change in afternoon trading Friday, extending a ...
Global health organisation CEPI will give roughly $60 million to Moderna and two other groups to accelerate the development of shots against Ebola Bundibugyo, the deadly virus that has swept through ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results